| 应用 |
A potent inhibitor of EGFR phosphorylation. |
| 产品介绍 |
AZD8931 (Sapitinib)是一种可逆的，ATP竞争性EGFR， ErbB2和ErbB3抑制剂，IC50分别为4 nM， 3 nM和4 nM，作用于NSCLC细胞比Gefitinib或Lapatinib更有效，作用于ErbB家族比作用于MNK1和Flt选择性强100倍。 |
| 备注 |
AZD8931 is a reversible, ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4 nM, 3 nM and 4 nM, more potent than Gefitinib or Lapatinib against NSCLC cell, 100-fold more selective for the ErbB family than MNK1 and |
| 生化机理 |
AZD8931 is an ATP competitive and reversible inhibitor of EGFR (ErbB-1), Neu (ErbB-2) and ErbB-3 (the IC50 values are 4 nM, 3 nM and 4 nM, respectively). |
| 别名 |
4-(3-氯-2-氟苯胺基)-7-甲氧基-6-[[1-(N-甲基氨基甲酰甲基)哌啶-4-基]氧基]喹唑啉;AZD 8931;4-(3-Chloro-2-fluoroanilino)-7-methoxy-6-[[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy]quinazoline; AZD 8931;Sapitinib |
